FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1895881123> ?p ?o ?g. }

• W1895881123 endingPage "32S" @default.
• W1895881123 startingPage "524S" @default.
• W1895881123 abstract "Recent evidence suggests that common molecular adaptations occur during resistance to both tamoxifen and estrogen deprivation that use various signal transduction pathways, often involving cross-talk with a retained and functional estrogen receptor (ER) protein. There appear to be several different levels at which this cross-talk may occur, including peptide growth factor signaling via the type 1 tyrosine kinase growth factor receptor family [epidermal growth factor receptor (EGFR) and HER2], which may become up-regulated during endocrine treatment, ultimately being harnessed by cells to allow them hormone-independent growth. ER may remain involved in cell growth with ligand-independent phosphorylation and activation via different intracellular mitogen-activated protein kinases. ER may also become involved in non-nuclear estrogen-dependent signaling via interaction with the phosphatidylinositol 3'-kinase/Akt cell survival pathway or may interact with the stress-activated protein kinase/c-Jun-NH(2)-terminal kinase pathway. Understanding these mechanisms will permit the optimal integration of new signal transduction inhibitors (STIs) into breast cancer therapy. Preclinical approaches that have shown promise include the use of EGFR tyrosine kinase inhibitors for hormone-resistant breast cancer cells that are dependent on either EGFR or HER2 signaling. Likewise, farnesyl transferase inhibitors, mitogen-activated protein kinase inhibitors, and cell cycle inhibitors have all shown activity in experimental breast cancer models. Emerging data suggest that STIs may be more effective when given in combination with endocrine therapy either to overcome resistance or to prevent/delay emergence of the resistance phenotype. Clinical trials are in progress to determine the safety and optimal schedule for each of the various STIs, and studies of STIs in combination with aromatase inhibitors have commenced in breast cancer to see whether the therapeutic response to endocrine therapy can be enhanced further." @default.
• W1895881123 created "2016-06-24" @default.
• W1895881123 creator A5003319899 @default.
• W1895881123 creator A5031915637 @default.
• W1895881123 creator A5035383163 @default.
• W1895881123 creator A5057689412 @default.
• W1895881123 creator A5077896405 @default.
• W1895881123 creator A5079758317 @default.
• W1895881123 creator A5091210130 @default.
• W1895881123 date "2003-01-01" @default.
• W1895881123 modified "2023-10-18" @default.
• W1895881123 title "Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer." @default.
• W1895881123 cites W1522280141 @default.
• W1895881123 cites W1558058709 @default.
• W1895881123 cites W1562190372 @default.
• W1895881123 cites W1564880184 @default.
• W1895881123 cites W1575537868 @default.
• W1895881123 cites W1590794385 @default.
• W1895881123 cites W1594384581 @default.
• W1895881123 cites W1617062315 @default.
• W1895881123 cites W1661647511 @default.
• W1895881123 cites W1889928106 @default.
• W1895881123 cites W1944037310 @default.
• W1895881123 cites W1964957120 @default.
• W1895881123 cites W1971147345 @default.
• W1895881123 cites W1971861967 @default.
• W1895881123 cites W1977221327 @default.
• W1895881123 cites W1999444744 @default.
• W1895881123 cites W2023384375 @default.
• W1895881123 cites W2052267264 @default.
• W1895881123 cites W2066425388 @default.
• W1895881123 cites W2083117834 @default.
• W1895881123 cites W2087729478 @default.
• W1895881123 cites W2088428799 @default.
• W1895881123 cites W2110068501 @default.
• W1895881123 cites W2115220780 @default.
• W1895881123 cites W2127779890 @default.
• W1895881123 cites W2128789136 @default.
• W1895881123 cites W2131362842 @default.
• W1895881123 cites W2132080332 @default.
• W1895881123 cites W2134001292 @default.
• W1895881123 cites W2135836172 @default.
• W1895881123 cites W2137343757 @default.
• W1895881123 cites W2142506125 @default.
• W1895881123 cites W2144785546 @default.
• W1895881123 cites W2146615732 @default.
• W1895881123 cites W2151463503 @default.
• W1895881123 cites W2151808231 @default.
• W1895881123 cites W2157650470 @default.
• W1895881123 cites W2160149526 @default.
• W1895881123 cites W2162517036 @default.
• W1895881123 cites W2163402367 @default.
• W1895881123 cites W2167368130 @default.
• W1895881123 cites W2335706708 @default.
• W1895881123 cites W2339143002 @default.
• W1895881123 cites W8163034 @default.
• W1895881123 cites W847266069 @default.
• W1895881123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12538510" @default.
• W1895881123 hasPublicationYear "2003" @default.
• W1895881123 type Work @default.
• W1895881123 sameAs 1895881123 @default.
• W1895881123 citedByCount "58" @default.
• W1895881123 countsByYear W18958811232012 @default.
• W1895881123 countsByYear W18958811232014 @default.
• W1895881123 countsByYear W18958811232015 @default.
• W1895881123 countsByYear W18958811232016 @default.
• W1895881123 countsByYear W18958811232017 @default.
• W1895881123 countsByYear W18958811232018 @default.
• W1895881123 countsByYear W18958811232021 @default.
• W1895881123 crossrefType "journal-article" @default.
• W1895881123 hasAuthorship W1895881123A5003319899 @default.
• W1895881123 hasAuthorship W1895881123A5031915637 @default.
• W1895881123 hasAuthorship W1895881123A5035383163 @default.
• W1895881123 hasAuthorship W1895881123A5057689412 @default.
• W1895881123 hasAuthorship W1895881123A5077896405 @default.
• W1895881123 hasAuthorship W1895881123A5079758317 @default.
• W1895881123 hasAuthorship W1895881123A5091210130 @default.
• W1895881123 hasConcept C121608353 @default.
• W1895881123 hasConcept C126322002 @default.
• W1895881123 hasConcept C184235292 @default.
• W1895881123 hasConcept C2777176818 @default.
• W1895881123 hasConcept C42362537 @default.
• W1895881123 hasConcept C502942594 @default.
• W1895881123 hasConcept C530470458 @default.
• W1895881123 hasConcept C62478195 @default.
• W1895881123 hasConcept C71924100 @default.
• W1895881123 hasConcept C75217442 @default.
• W1895881123 hasConcept C84606932 @default.
• W1895881123 hasConcept C86803240 @default.
• W1895881123 hasConcept C95444343 @default.
• W1895881123 hasConcept C97029542 @default.
• W1895881123 hasConceptScore W1895881123C121608353 @default.
• W1895881123 hasConceptScore W1895881123C126322002 @default.
• W1895881123 hasConceptScore W1895881123C184235292 @default.
• W1895881123 hasConceptScore W1895881123C2777176818 @default.
• W1895881123 hasConceptScore W1895881123C42362537 @default.
• W1895881123 hasConceptScore W1895881123C502942594 @default.
• W1895881123 hasConceptScore W1895881123C530470458 @default.

• next